In her recent interview, Dr. Snyder stresses that it’s particularly important for patients to take PsA drugs exactly as prescribed, in order to achieve optimal therapeutic outcomes.
Dr. Nelson provided expert opinion regarding the drug, which was being evaluated as a potential new treatment for arthritis pain.
The allergists provided useful information on both conditions, and discussed what to do if someone suspects they are experiencing symptoms.
The specially modified nanoparticles have the capability of delivering therapeutic drugs to inflammation sites.
The award is presented to the top junior biology major based on academic & research excellence, and contributions to the Biology Department.
The new research findings show that high intensity training was not more beneficial than lower intensity training or a healthy education control intervention.
Dr. Golightly is an internationally recognized osteoarthritis researcher and epidemiologist.
The article provides a review of previous, current and evolving views regarding the disease, including treatments ranging from behavior modification, to advanced new therapies.
Dr. Rumey Ishizawar founded the multi-disciplinary UNC Immuno-Oncology Group (IOG) in 2017 to optimize clinical management of cancer patients who develop immune related adverse events (irAEs).
The objective of the pilot and feasibility program is to provide seed money of up to $25K for 1 year to initiate new and innovative projects in the areas of phenotyping and precision medicine that will enhance work being done in the CCCR.